Identification of cost-effective biomarkers for Alzheimer's disease
Approved Research ID: 95105
Approval date: December 20th 2022
Major approaches to identify the presence of Alzheimers' Disease ( AD ) are mini-mental state examination(MMSE) and MRI of the brain currently. However, patients in some area have
difficulties in accessing the expensive MRI facility. The number of the patients who can access
MRI facility is increasing year by year. Thus the cost of MRI is also increasing. Therefore in order to accommodate the patients without MRI data and reduce the NHS cost for MRI scan there is a need to find a way to diagnose AD at a lower cost than currently experiencing.
Blood, urine and saliva are the cheap biomarkers and there are some reports on the correlation
between such biomarkers and the diagnosis of AD. This project makes best use of the vast
data available in UKBiobank to identify the key biomarkers for the diagnosis of the AD and develops a system which can use the information from the low-cost biomarkers and MMSE score to diagnose AD. The project outcome will lower the cost incurred on NHS system and give patients a faster diagnosis than currently experiencing.